A newly formed fund called MS1 has acquired a portfolio of interests in six clinical- and pre-clinical-stage companies from Index Venture Life VI – a life sciences fund advised by Medicxi.
Fund invests in renewable chemistry, regenerative medicine and agri-food across the Netherlands, Belgium and parts of Germany
Company will operate with the GP's existing test and measurement companies in the US and Denmark
Numerous Italian GPs with a generalist approach have reshaped their activity towards the tech sector
GP plans to merge Atlantic with portfolio company Maced, in which it acquired a majority stake last year